Paul Belsky - Heat Biologics Independent Director
Director
Dr. Paul Belsky M.D. is an Independent Director of the Company. Dr. Belsky served as a scientific advisor to SeedOne Ventures Elusys Therapeutics Sensatex GenerationOne and TyRx Pharma. Dr. Belsky has extensive expertise in the clinical practice of internal medicine and cardiovascular diseases and was formerly on the clinical academic faculty at Weill College of Medicine Cornell University. He is a fellow of the American College of Cardiology and the American College of Chest Physicians is a member of the American College of Physicians and a Clinical Assistant Professor of Medicine at New York University School of Medicine. Dr. Belsky received his M.D. from the University of California at San Francisco and his AB in Biology from Brown University where he was elected Phi Beta Kappa. since 2009.
Age | 58 |
Tenure | 15 years |
Phone | 919 240 7133 |
Web | https://www.heatbio.com |
Heat Biologics Management Efficiency
The company has return on total asset (ROA) of (17.1) % which means that it has lost $17.1 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.12) %, meaning that it created substantial loss on money invested by shareholders. Heat Biologics' management efficiency ratios could be used to measure how well Heat Biologics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.93 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Heat Biologics has a current ratio of 20.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Heat Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Heat Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Heat Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Heat to invest in growth at high rates of return. When we think about Heat Biologics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Ireena Vittal | Diageo PLC ADR | 51 | |
Chad Deaton | Transocean | 61 | |
Stanley Sheridan | National Beverage Corp | 73 | |
Vincent Intrieri | Transocean | 63 | |
Cecil Conlee | National Beverage Corp | 80 | |
Lavonne Zdunich | Precision Drilling | N/A | |
Nicola Mendelsohn | Diageo PLC ADR | 47 | |
Frederick Dyment | Major Drilling Group | 68 | |
Samuel Hathorn | National Beverage Corp | 73 | |
Anna Manz | Diageo PLC ADR | 42 | |
Edward Muller | Transocean | 68 | |
David Williams | Precision Drilling | 62 | |
Catherine Hughes | Precision Drilling | 53 | |
Emma Walmsley | Diageo PLC ADR | 46 | |
Leanne Wood | Diageo PLC ADR | 41 | |
Alison Johnson | Transocean | N/A | |
Susan MacKenzie | Precision Drilling | 59 | |
Margareth Ovrum | Transocean | 62 | |
Valerie ChapoulaudFloquet | Diageo PLC ADR | 58 | |
Charlotte Lambkin | Diageo PLC ADR | 43 | |
Siobhan Moriarty | Diageo PLC ADR | 54 |
Management Performance
Return On Equity | -31.12 | |||
Return On Asset | -17.1 |
Heat Biologics Leadership Team
Elected by the shareholders, the Heat Biologics' board of directors comprises two types of representatives: Heat Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heat. The board's role is to monitor Heat Biologics' management team and ensure that shareholders' interests are well served. Heat Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heat Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Smith, Independent Director | ||
Timothy Creech, CFO | ||
Melissa Price, VP of Product Devel. | ||
John Monahan, Independent Director | ||
Louis Bock, Independent Director | ||
Taylor Schreiber, Vice President - Research and Development | ||
Ann Rosar, Vice President - Finance, Corporate Secretary | ||
Paul Belsky, Independent Director | ||
Mark Weinberg, Executive Vice President - Clinical Development | ||
Anil Goyal, VP of Bus. Devel. | ||
Jeff Hutchins, Chief Scientific Officer, Senior Vice President - Pre-Clinical Development | ||
Michael Kharitonov, Independent Director | ||
Robert Jakobs, Controller | ||
John Prendergast, Director | ||
Melissa Conger, IR Contact Officer | ||
Jeffrey Wolf, Chairman of the Board, CEO | ||
Durham NC, IR Contact Officer |
Heat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heat Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -31.12 | |||
Return On Asset | -17.1 | |||
Current Valuation | (34.74 M) | |||
Shares Outstanding | 25.4 M | |||
Shares Owned By Insiders | 5.20 % | |||
Shares Owned By Institutions | 10.77 % | |||
Number Of Shares Shorted | 1.17 M | |||
Price To Earning | (1.29) X | |||
Price To Book | 0.48 X | |||
Price To Sales | 28.62 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Heat Stock
If you are still planning to invest in Heat Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Heat Biologics' history and understand the potential risks before investing.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Transaction History View history of all your transactions and understand their impact on performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |